San Mateo, United States
PrognomiQ Inc aims to revolutionize healthcare and early disease detection through its pioneering use of multi-omics data. Founded in 2020 and headquartered in the United States, PrognomiQ's approach focuses on generating highly accurate proteomic information swiftly and at scale. By integrating this with genomic, metabolomic, and other health data, the company seeks to create cutting-edge test products to enhance early disease detection and treatment.
Historically, proteomics faced substantial technical and economic challenges, leaving its potential largely unexplored in clinical settings. PrognomiQ overcomes these hurdles using advanced tools, like the Proteograph technology platform from its progenitor, Seer (NASDAQ: SEER). This breakthrough enables the collection of complex proteomics data, providing direct insights into the biological state of cells.
Recently, PrognomiQ secured a $10.00M Late VC investment as of 01 August 2025, positioning it well for further development. Investors will find value in its innovative multi-omics platform, addressing early-stage disease detection—an area with significant potential for transformative healthcare impact.
Biodesix, Inc.
Bertis Inc
